Possible role of tryptophan metabolism along the microbiota-gut-brain axis on cognitive & behavioral aspects in Phenylketonuria
Copyright © 2023 The Authors. Published by Elsevier Ltd.. All rights reserved..
Cognitive and psychiatric disorders are well documented across the lifetime of patients with inborn errors of metabolism (IEMs). Gut microbiota impacts behavior and cognitive functions through the gut-brain axis (GBA). According to recent research, a broad spectrum of GBA disorders may be influenced by a perturbed Tryptophan (Trp) metabolism and are associated with alterations in composition or function of the gut microbiota. Furthermore, early-life diets may influence children's neurodevelopment and cognitive deficits in adulthood. In Phenylketonuria (PKU), since the main therapeutic intervention is based on a life-long restrictive diet, important alterations of gut microbiota have been observed. Studies on PKU highlight the impact of alterations of gut microbiota on the central nervous system (CNS), also investigating the involvement of metabolic pathways, such as Trp and kynurenine (KYN) metabolisms, involved in numerous neurodegenerative disorders. An alteration of Trp metabolism with an imbalance of the KYN pathway towards the production of neurotoxic metabolites implicated in numerous neurodegenerative and inflammatory diseases has been observed in PKU patients supplemented with Phe-free amino acid medical foods (AA-MF). The present review investigates the possible link between gut microbiota and the brain in IEMs, focusing on Trp metabolism in PKU. Considering the evidence collected, cognitive and behavioral well-being should always be monitored in routine IEMs clinical management. Further studies are required to evaluate the possible impact of Trp metabolism, through gut microbiota, on cognitive and behavioral functions in IEMs, to identify innovative dietetic strategies and improve quality of life and mental health of these patients.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:197 |
|---|---|
| Enthalten in: |
Pharmacological research - 197(2023) vom: 30. Nov., Seite 106952 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Parolisi, Sara [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
8DUH1N11BX |
|---|
| Anmerkungen: |
Date Completed 21.11.2023 Date Revised 21.11.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.phrs.2023.106952 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM362985170 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM362985170 | ||
| 003 | DE-627 | ||
| 005 | 20231226092402.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.phrs.2023.106952 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1209.xml |
| 035 | |a (DE-627)NLM362985170 | ||
| 035 | |a (NLM)37804926 | ||
| 035 | |a (PII)S1043-6618(23)00308-0 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Parolisi, Sara |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Possible role of tryptophan metabolism along the microbiota-gut-brain axis on cognitive & behavioral aspects in Phenylketonuria |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 21.11.2023 | ||
| 500 | |a Date Revised 21.11.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023 The Authors. Published by Elsevier Ltd.. All rights reserved. | ||
| 520 | |a Cognitive and psychiatric disorders are well documented across the lifetime of patients with inborn errors of metabolism (IEMs). Gut microbiota impacts behavior and cognitive functions through the gut-brain axis (GBA). According to recent research, a broad spectrum of GBA disorders may be influenced by a perturbed Tryptophan (Trp) metabolism and are associated with alterations in composition or function of the gut microbiota. Furthermore, early-life diets may influence children's neurodevelopment and cognitive deficits in adulthood. In Phenylketonuria (PKU), since the main therapeutic intervention is based on a life-long restrictive diet, important alterations of gut microbiota have been observed. Studies on PKU highlight the impact of alterations of gut microbiota on the central nervous system (CNS), also investigating the involvement of metabolic pathways, such as Trp and kynurenine (KYN) metabolisms, involved in numerous neurodegenerative disorders. An alteration of Trp metabolism with an imbalance of the KYN pathway towards the production of neurotoxic metabolites implicated in numerous neurodegenerative and inflammatory diseases has been observed in PKU patients supplemented with Phe-free amino acid medical foods (AA-MF). The present review investigates the possible link between gut microbiota and the brain in IEMs, focusing on Trp metabolism in PKU. Considering the evidence collected, cognitive and behavioral well-being should always be monitored in routine IEMs clinical management. Further studies are required to evaluate the possible impact of Trp metabolism, through gut microbiota, on cognitive and behavioral functions in IEMs, to identify innovative dietetic strategies and improve quality of life and mental health of these patients | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Cognitive-behavioral development | |
| 650 | 4 | |a Inborn errors metabolism | |
| 650 | 4 | |a Kynurenine | |
| 650 | 4 | |a Microbiota-gut-brain axis | |
| 650 | 4 | |a Phenylketonuria | |
| 650 | 4 | |a Tryptophan metabolism | |
| 650 | 7 | |a Tryptophan |2 NLM | |
| 650 | 7 | |a 8DUH1N11BX |2 NLM | |
| 700 | 1 | |a Montanari, Chiara |e verfasserin |4 aut | |
| 700 | 1 | |a Borghi, Elisa |e verfasserin |4 aut | |
| 700 | 1 | |a Cazzorla, Chiara |e verfasserin |4 aut | |
| 700 | 1 | |a Zuvadelli, Juri |e verfasserin |4 aut | |
| 700 | 1 | |a Tosi, Martina |e verfasserin |4 aut | |
| 700 | 1 | |a Barone, Rita |e verfasserin |4 aut | |
| 700 | 1 | |a Bensi, Giulia |e verfasserin |4 aut | |
| 700 | 1 | |a Bonfanti, Cristina |e verfasserin |4 aut | |
| 700 | 1 | |a Dionisi Vici, Carlo |e verfasserin |4 aut | |
| 700 | 1 | |a Biasucci, Giacomo |e verfasserin |4 aut | |
| 700 | 1 | |a Burlina, Alberto |e verfasserin |4 aut | |
| 700 | 1 | |a Carbone, Maria T |e verfasserin |4 aut | |
| 700 | 1 | |a Verduci, Elvira |e verfasserin |4 aut | |
| 700 | 0 | |a SIMMESN Working Group for Gut Microbiota in Inborn Errors of Metabolism |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Pharmacological research |d 1992 |g 197(2023) vom: 30. Nov., Seite 106952 |w (DE-627)NLM012597384 |x 1096-1186 |7 nnns |
| 773 | 1 | 8 | |g volume:197 |g year:2023 |g day:30 |g month:11 |g pages:106952 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.phrs.2023.106952 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 197 |j 2023 |b 30 |c 11 |h 106952 | ||